1222090-71-2Relevant academic research and scientific papers
Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles
Wang, Yingcai,Liu, Jiwen,Dransfield, Paul J.,Zhu, Liusheng,Wang, Zhongyu,Du, Xiaohui,Jiao, Xianyun,Su, Yongli,Li, An-Rong,Brown, Sean P.,Kasparian, Annie,Vimolratana, Marc,Yu, Ming,Pattaropong, Vatee,Houze, Jonathan B.,Swaminath, Gayathri,Tran, Thanhvien,Nguyen, Khanh,Guo, Qi,Zhang, Jane,Zhuang, Run,Li, Frank,Miao, Lynn,Bartberger, Michael D.,Correll, Tiffany L.,Chow, David,Wong, Simon,Luo, Jian,Lin, Daniel C.-H.,Medina, Julio C.
, p. 551 - 555 (2013)
GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this repor
SPIROCYCLIC GPR40 MODULATORS
-
Page/Page column 96, (2010/04/30)
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also
